Nuvectis Pharma, Inc. (NVCT)
| Market Cap | 289.13M +17.8% |
| Revenue (ttm) | n/a |
| Net Income | -29.59M |
| EPS | -1.30 |
| Shares Out | 26.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,084 |
| Open | 10.98 |
| Previous Close | 11.06 |
| Day's Range | 10.38 - 11.09 |
| 52-Week Range | 5.55 - 11.85 |
| Beta | -0.12 |
| Analysts | Strong Buy |
| Price Target | 10.00 (-8.26%) |
| Earnings Date | May 5, 2026 |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NVCT stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma management to meet with Maxim
Meeting to be held on March 25 hosted by Maxim.
Nuvectis Pharma files $150M mixed securities shelf
16:03 EST Nuvectis Pharma (NVCT) files $150M mixed securities shelf
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
Nuvectis Pharma announces initiation of Phase 1b study of NXP900
Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is…
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c...
Nuvectis Pharma Transcript: KOL Event
NXP900, a novel oral Src inhibitor, is advancing in a broad phase 1b program targeting major unmet needs in advanced solid tumors, especially non-small cell lung cancer. Early data show high Src inhibition and favorable tolerability, with multiple combination studies and data readouts expected in 2026.
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medic...
Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on advancing the clinical work required to support our ambitious Phase 1b program…
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The...
Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on advancing the clinical work required to support our ambitious Phase 1b program…
Nuvectis Pharma provides highlights from NXP900 poster presentations
Nuvectis Pharma (NVCT) provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in...
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the tr...
Nuvectis Pharma appoints Juan Sanchez to board of directors
Nuvectis Pharma (NVCT) announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine,…
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma Transcript: Status Update
Phase 1B study for NXP900 has begun, targeting genetically defined advanced cancers as both monotherapy and in combination with EGFR/ALK inhibitors. The program leverages a strong cash position, robust preclinical and clinical data, and aims for significant market and regulatory milestones.
Nuvectis Pharma initiates NXP900 program
Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b program for NXP900.
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat...
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
Cash and cash equivalents were $26.8M vs. $18.5M as of December 31, 2024. CEO Ron Bentsur commented, “In Q2 and subsequent weeks we have had a series of important events…
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Nuvectis Pharma (NVCT) to $10 from $15 and keeps a Buy rating on the shares. The firm removed NXP800 from its projections.
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
Nuvectis Pharma (NVCT) provided the final clinical data update from the Phase 1b study of NXP800 in recurrent, platinum resistant, ARID1a-mutated ovarian cancer and reported on the progress towards th...
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases...
Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer
Nuvectis Pharma (NVCT) announced the completion of a clinical DDI study in healthy volunteers for NXP900, supporting NXP900’s potential as a combination partner with leading therapies. Drug-drug inter...